RT Journal Article
SR Electronic
T1 SARS-CoV-2 antibody prevalence and symptoms in a local Austrian population
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.03.20219121
DO 10.1101/2020.11.03.20219121
A1 Ladage, Dennis
A1 Höglinger, Yana
A1 Ladage, Dorothee
A1 Adler, Christoph
A1 Yalcin, Israfil
A1 Braun, Ralf J.
YR 2020
UL http://medrxiv.org/content/early/2020/11/04/2020.11.03.20219121.abstract
AB Background Since December 2019 the novel coronavirus (SARS-CoV-2) is the center of global attention due to its rapid transmission and toll on health care systems and global economy. Population-based serosurveys measuring antibodies for SARS-CoV-2 provide one method for estimating infection rates and monitoring the progression of the epidemic.Methods In June 2020 we succeeded in testing almost half of the population of an Austrian township (n=835 of 1359 inhabitants) with a reported higher incidence for COVID-19 infections. We determined the level of prevalence for SARS-CoV-2 in this population, factors affecting, and symptoms correlated with prior infection.Results We found a high prevalence of 9% positive antibodies among the town population in comparison to 6% of the neighboring villages. Only 20% of SARS-CoV-2 cases self-declared being asymptomatic. In contrast, we identified six single major symptoms, including anosmia/ageusia, weight loss, anorexia, general debility, dyspnea, and fever, and especially their combination to be of high prognostic value for predicting SARS-CoV-2 infection in a patient. Our comparison of the gold standard lab-based ELISA test and the on-site antibody test demonstrated a lack of accuracy for the latter test form.Conclusions This population study demonstrated a high prevalence of antibodies to SARS-CoV-2 as a marker of both active and past infections in an Austrian township. Several symptoms revealed a diagnostic value especially in combination. Results from self-administered antibody tests should be considered with caution.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialObservational pilot studyFunding StatementNo external funding to report.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Data was obtained observing national ethical guidelines. The study was reported to the ethics committee of Lower Austria (Niederoesterreich), by decision of the committee (letter from director of the board Robert Brucker) a ruling was waived due to the nature of the study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data for this manuscript is available.